Global News and Digital Insights
for the Healthcare Industry

The FDA has urged Pfizer to test efficacy of additional Paxlovid’s course on COVID-19 relapse patients

The US Food and Drug Administration (FDA) has asked Pfizer to test its antiviral Paxlovid’s second course on people with COVID-19 rebound. The pharma giant has been asked to generate initial results of a randomised controlled trial of a Paxlovid’s additional course by September 30, 2023. The research protocol is most likely to be settled this month. Pfizer and the FDA are said to be working together to devise a protocol for patients who have relapsed and may need additional treatment.

Read More from Reuters